Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | NPC1 | O15118 | 8/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | ACACB | O00763 | 1/20 | 0.58 |
| ▸ | ACACA | Q13085 | 1/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14339592 | 0.96 | NOTUM (0.64) | NOTUMHTR1AHRH3RAB9ANPC1 | |
| Dimethylamine SCHEMBL7947230 | 0.95 | NOTUM (0.62) | NOTUMHTR1AHRH3RAB9ANPC1 | |
| SCHEMBL14288613 | 0.85 | RAB9A (0.70) | NOTUMHTR1AHRH3RAB9ANPC1 | |
| SCHEMBL10053485 | 0.83 | SMN1; SMN2 (0.63) | RAB9ANPC1L3MBTL1MAPTTSHR | |
| SCHEMBL12525780 | 0.83 | MAPT (0.61) | NOTUMRAB9ANPC1L3MBTL1CYP1A2 | |
| SCHEMBL8592557 | 0.81 | ACACB (0.59) | NOTUMHTR1AHRH3RAB9ANPC1 | |
| SCHEMBL315371 | 0.81 | ACACB (0.55) | NOTUMHTR1AHRH3RAB9ANPC1 | |
| SCHEMBL201607 | 0.81 | NOTUM (0.70) | NOTUMRAB9ANPC1L3MBTL1CYP1A2 | |
| SCHEMBL6112858 | 0.81 | ACACB (0.59) | NOTUMRAB9ANPC1MAPTSMN1; SMN2 | |
| SCHEMBL5311162 | 0.81 | ACACB (0.59) | NOTUMHTR1AHRH3RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021231615-A1 | SUBSTITUTED PYRIDAZINONE FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| EP-3725785-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-21 | — | — | EP | disclosed |
| EP-3722290-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-14 | — | — | EP | disclosed |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2020-03-05 | — | — | US | disclosed |
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-RE46375-E1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-RE46365-E1 | 6,7-unsaturated-7-carbamoyl substituted morphinan derivative | SHIONOGI & CO., LTD. (JP) | 2017-04-11 | — | — | US | disclosed |
| WO-2007115278-A2 | 3,6,11-TRICYCLOLIDE | ENANTA PHARMACEUTICALS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | ENATA PHARMACEUTICALS, INC. | 2007-10-04 | — | — | US | disclosed |
| US-7273853-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| US-7229972-B2 | Semisynthetic trimethylenedioxy-erythromycin derivatives and their use in treating bacterial infections and cystic fibrosis; preparation | ENANTA PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1553949-B1 | PYRIMIDINE-2,4-DIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-18 | — | — | EP | disclosed |
| US-7189704-B2 | 6-11 bicyclic ketolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-7169786-B2 | Isoxazoline derivatives as anti-depressants | JANSSEN-CILAG S.A. (ES) | 2007-01-30 | — | — | US | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160893-B2 | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305863-A1 | N-((HET) ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | NOTUM 994/4885HTR1A 712/4885HRH3 40/4885 |
| US-20200071273-A1 | QUINOLONE-BASED COMPOUNDS WITH ANTICANCER ACTIVITY | TOP2A, TOP2B, TOP1 | NOTUM 3217/4885HTR1A 3485/4885HRH3 4803/4885 |
| US-20170151239-A1 | 2,4-Pyrimidinediamine Compounds and Their Uses | FCER2, FCGR1A, FCGR2A | NOTUM 2472/4885HTR1A 192/4885HRH3 22/4885 |
| US-10781181-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | NOTUM 994/4885HTR1A 712/4885HRH3 40/4885 |
| US-20070232554-A1 | 3,6-Bridged 9,12-oxolides | CYP2C9, CYP2C19, CYP2D6 | NOTUM 1113/4885HTR1A 4808/4885HRH3 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.